Oral-ATO for TP53-mutated Myeloid Malignancies

NCT06778187 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Neoplasm
Chronic Myelomonocytic Leukemia
TP53 Gene Mutation
Arsenic Trioxide

Interventions

DRUG: Oral arsenic trioxide

Sponsor

The University of Hong Kong